CN114478828A - Detection material, detector and detection method for circulating tumor cells - Google Patents

Detection material, detector and detection method for circulating tumor cells Download PDF

Info

Publication number
CN114478828A
CN114478828A CN202111494317.1A CN202111494317A CN114478828A CN 114478828 A CN114478828 A CN 114478828A CN 202111494317 A CN202111494317 A CN 202111494317A CN 114478828 A CN114478828 A CN 114478828A
Authority
CN
China
Prior art keywords
circulating tumor
chitosan
bio
substrate
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202111494317.1A
Other languages
Chinese (zh)
Other versions
CN114478828B (en
Inventor
王怀雨
劳智奇
李伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Institute of Advanced Technology of CAS
Original Assignee
Shenzhen Institute of Advanced Technology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Institute of Advanced Technology of CAS filed Critical Shenzhen Institute of Advanced Technology of CAS
Priority to CN202111494317.1A priority Critical patent/CN114478828B/en
Publication of CN114478828A publication Critical patent/CN114478828A/en
Priority to PCT/CN2022/137032 priority patent/WO2023104059A1/en
Application granted granted Critical
Publication of CN114478828B publication Critical patent/CN114478828B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/00272-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57438Specifically defined cancers of liver, pancreas or kidney

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention discloses a detection material, a detector and a detection method of circulating tumor cells, wherein the detection material of the circulating tumor cells is fixed on a substrate, and the detection material is chitosan modified by functional groups; the functional group comprises a bio-orthogonal reactive group; or include bio-orthogonal reactive groups and reversible reactive groups. The detector for the circulating tumor cells comprises a substrate and the detection material fixed on the substrate. The novel material for detecting the circulating tumor cells can play a biorthogonal/anti-adhesion dual function or a biorthogonal/anti-adhesion/reversible release function according to different modification degrees, and the chitosan replaces gold to be used as a functionalized surface, so that the cost is reduced; the bioorthogonal chitosan surface has good anti-adhesion effect, the detection precision is improved, and the probability of false positive detection results is reduced.

Description

Detection material, detector and detection method for circulating tumor cells
Technical Field
The invention belongs to the technical field of biological materials, and particularly relates to a detection material, a detector and a detection method for circulating tumor cells.
Background
In 1869, the concept of Circulating Tumor Cells (CTCs) was first discovered and proposed by Ashworth, an australian physician, in the blood of breast cancer patients. In 1976 Nowell revised the definition of CTC to: derived from primary or metastatic tumors, acquire the ability to detach from the basement membrane and invade tumor cells that enter the blood vessels through the tissue matrix. CTC is now a generic term for the various types of tumor cells present in peripheral blood that grow and spread throughout the various stages of tumor growth.
Liver cancer is one of the six common tumors, with the first three fatality rates among all cancers. Early diagnosis and treatment are difficult points for clinically dealing with liver cancer treatment. Early screening is beneficial to prolonging the survival time of liver cancer patients, and early diagnosis is also beneficial to adopting various treatment modes, thereby improving prognosis. However, only about 35% of patients with liver cancer can be treated effectively in the early stage clinically, and only a few biomarkers can be used as the evaluation index of liver cancer, among which Alpha Fetoprotein (AFP) is the most widely used biomarker. However, AFP has certain limitations, such as a high proportion of false positive results, lack of sufficient sensitivity and specificity.
The CTC detection method (CN113358865A) based on the bioorthogonal metabolic sugar engineering marker realizes the accurate and nondestructive detection of CTC through the detection process of 'marker-capture-release'. The method comprises the steps of firstly designing a CTC marking process based on metabolic sugar engineering, processing a sample by utilizing a marker molecule based on a sugar unit, and artificially marking CTC by the marker molecule through the metabolic sugar engineering; secondly, designing and synthesizing capture molecules simultaneously containing bioorthogonal groups and reversible reaction groups, preparing a detection device integrating capture/release functions by fixing the capture molecules on a device substrate (such as a microfluidic chip, a magnetic nanoparticle material and the like) through reversible reaction, and capturing CTC by performing bioorthogonal reaction with CTC surface marker groups; finally, release molecules are designed to be introduced, and captured CTCs can be released by exchanging capture molecules immobilized on the substrate of the detection device through a reversible reaction.
The existing circulating tumor cell detection material based on the bioorthogonal reaction is obtained by directly carrying out small molecule bioorthogonal modification on gold serving as a substrate. However, due to the existence of tumor heterogeneity, the adhesion of the liver cancer CTC on the bio-orthorhombic gold surface is weak, the nonspecific adhesion is strong, and the detection effect of the bio-orthorhombic gold surface in the CTC detection method (CN113358865A) of the bio-orthorhombic glycoengineering marker is poor and the false positive is high when the liver cancer is detected. The key to overcoming the technical bottleneck of the detection of the liver cancer CTC is to find a functionalized surface suitable for the detection of the liver cancer CTC.
Chitosan is an N-deacetylation product of chitin, the second most abundant natural polysaccharide in nature, second only to cellulose. Chitosan has many useful properties such as biocompatibility, biodegradability, antibacterial activity, wound healing properties, anti-tumor effect, etc.
In recent years, because the chitosan coating has more modifiable sites, the chitosan coating is functionally modified, and thus, researches on application of the chitosan coating to aspects of basic medicine, disease treatment, medical detection and the like are increasing.
Disclosure of Invention
In order to overcome the defects in the prior art, the invention aims to provide a detection material, a detector and a detection method for circulating tumor cells. The invention provides a material for CTC detection and a preparation method and a using method thereof. The novel CTC detector is mainly prepared by performing substrate surface coating-functionalized modification on commercially available chitosan, and is finally applied to CTC detection. The chitosan coating which is uniform and suitable for downstream application is prepared on the surface coating of the substrate by methods of spin coating, electrostatic spinning and the like; based on the characteristic that chitosan molecules have amino groups which exist regularly and are easy to modify, the required reversible reaction connecting arm and the bioorthogonal/anti-adhesion bifunctional group are gradually connected to the amino site of the chitosan through a chemical method; based on the principle of 'high specificity affinity and low non-specificity affinity', the accuracy of CTC detection is finally improved.
The invention provides a detection material for circulating tumor cells, which is fixed on a substrate and is chitosan modified by functional groups;
(1) the functional group comprises a bio-orthogonal reactive group; or the like, or, alternatively,
(2) the functional groups include bio-orthogonal reactive groups and reversible reactive groups.
Further, (1) when the functional group comprises a bio-orthogonal reaction group, the detection material has a structure shown in the following formula I,
Figure BDA0003399597180000021
the R is a bio-orthogonal reactive group;
preferably, R has a structure represented by formula A, B, C or D,
Figure BDA0003399597180000031
(2) when the functional group comprises a bio-orthogonal reactive group and a reversible reactive group, the reversible reactive group is a disulfide bond;
preferably, the reversible reactive group serves as a linking arm to link the chitosan and the bio-orthogonal reactive group;
preferably, the detection material has a structure shown in the following formula II,
Figure BDA0003399597180000032
the R is a bio-orthogonal reactive group;
preferably, R has a structure represented by formula A, B, C or D,
Figure BDA0003399597180000033
in the above technical solution of the present invention, the substrate has a hydrophilic surface;
preferably, the substrate is selected from hydrophilized glass, silicon wafers or mica.
In a second aspect, the invention provides a detector of circulating tumor cells, the detector comprising a substrate and the detection material immobilized on the substrate.
In the above technical solution of the present invention, the substrate has a hydrophilic surface;
preferably, the substrate is selected from a microfluidic chip substrate, a magnetic nanoparticle material substrate and other material substrates capable of being subjected to hydrophilization treatment.
In a third aspect, the invention provides a detection kit for circulating tumor cells, which comprises the detection material or the detector and a sugar unit-based labeling molecule;
preferably, the detection kit further comprises a release molecule;
preferably, the releasing molecule is dithiothreitol and/or a borate;
preferably, the sugar unit-based labeling molecule is selected from one or more of a 2-amino mannose unit, a 2-amino galactose unit, a 2-amino glucose unit and a 6-azide-L-fucose unit;
the 2-amino mannose unit, the 2-amino galactose unit, the 2-amino glucose unit and the 6-azido-L-fucose unit have the following structures,
Figure BDA0003399597180000041
wherein X is (CH)2)n. Preferably, n is 1, 2, 3, 4, 5, 6.
The fourth aspect of the invention provides the use of the material for detecting circulating tumor cells, the detector for circulating tumor cells or the detection kit for circulating tumor cells in circulating tumor cell detection;
preferably, the circulating tumor cell is a circulating tumor cell of liver cancer.
The fifth aspect of the present invention provides a method for preparing the material for detecting circulating tumor cells, comprising the following steps:
preparing a chitosan coating: preparing a chitosan coating on the surface of a substrate material, and adjusting the pH value to expose chitosan amino;
functional modification of the chitosan coating: connecting a bio-orthogonal reaction group or a bio-orthogonal reaction group and a reversible reaction group on a chitosan molecule;
preferably, uniformly spreading acetic acid solution of chitosan on the surface of the substrate material, drying and adjusting pH to obtain a chitosan coating;
preferably, the acetic acid solution of chitosan is uniformly spread on the surface of the substrate material by means of spin coating or electrostatic spinning;
preferably, the chitosan has a degree of deacetylation of 95%;
preferably, the volume percentage of the acetic acid solution is 90%.
In the technical scheme of the invention, when the functionalized groups comprise bio-orthogonal reactive groups, the chitosan coating is functionally modified by reacting the chitosan coating with NHS activated ester containing the bio-orthogonal reactive groups in ethanol containing 5% of triethylamine for 24 hours; 5 times of ethanol washing with 5% triethylamine, 3 times of water washing with 5% triethylamine, and 3 times of water washing; drying for 1 hour at 60 ℃;
when the functional groups comprise bio-orthogonal reaction groups and reversible reaction groups, the functional modification method of the chitosan coating is that the chitosan coating reacts with coupling molecules SPDP in ethanol containing 5% of triethylamine for 24 hours; 5 times of ethanol washing with 5% triethylamine, 3 times of water washing with 5% triethylamine, and 3 times of water washing; drying for 1 hour at 60 ℃; reacting with thiol-modified bio-orthogonal reactive group-containing molecules in ethanol for 24 hours; washing with ethanol for 5 times, and washing with water for 5 times; drying for 1 hour at 60 ℃.
The sixth aspect of the present invention provides a method for detecting circulating tumor cells, comprising the steps of:
processing a sample by using a marker molecule based on a sugar unit, and artificially marking the circulating tumor cells by the marker molecule through metabolic sugar engineering;
co-incubating the circulating tumor cells with the detection material or the detector, wherein a bio-orthogonal reaction group and a marker molecule generate a bio-orthogonal reaction, and the circulating tumor cells are captured;
preferably, when the functionalized groups include bio-orthogonal reactive groups and reversible reactive groups, the detection method further comprises releasing the captured circulating tumor cells, in particular: cleaving the reversible reactive group to release the captured circulating tumor cell by adding a release molecule to the captured circulating tumor cell or by regulating an electrical signal and/or temperature of the functionalized surface of the captured circulating tumor cell;
preferably, the releasing molecule is dithiothreitol and/or a borate;
preferably, the circulating tumor cell is a circulating tumor cell of liver cancer.
The invention has the beneficial effects that:
1. the invention provides a novel material for detecting circulating tumor cells, which is chitosan modified by functional groups, and can play the roles of bioorthogonality/anti-adhesion or bioorthogonality/anti-adhesion/reversible release according to different modification degrees, thereby meeting the aim of detecting different CTC (cytotoxic T cell) such as CTC counting, CTC downstream physiological and biochemical analysis and the like. Its main advantage is as follows:
(1) the chitosan replaces gold to be used as the functionalized surface, so that the cost is reduced.
(2) The bioorthogonal chitosan surface has good anti-adhesion effect, the detection precision is improved, and the probability of false positive detection results is reduced.
(3) The chitosan coating can be uniformly spread on almost all hydrophilic surfaces in a dissolving and drying mode, and detectors with different physical shapes and properties can be conveniently prepared. Compared with a gold surface, the detector has the advantages of mild preparation conditions, wide universality and better effect.
2. The material for detecting the circulating tumor cells provided by the invention utilizes the physicochemical property of bioorthogonal chitosan to improve the adhesion of the liver cancer CTC to the material and reduce the non-specific adhesion of leukocytes on the liver cancer CTC, thereby improving the detection effect, reducing the false positive rate and filling the blank of a liver cancer circulating tumor cell detection technology.
Drawings
FIG. 1 is a diagram of the overall process of the detection of CTC in liver cancer according to the present invention.
FIG. 2 is a method of cleaving a reversibly reactive group.
Detailed Description
In order that the invention may be more clearly understood, it will now be further described with reference to the following examples and the accompanying drawings. The examples are for illustration only and do not limit the invention in any way. In the examples, each raw reagent material is commercially available, and the experimental method not specifying the specific conditions is a conventional method and a conventional condition well known in the art, or a condition recommended by an instrument manufacturer.
"bioorthogonal" refers to having groups that can undergo bioorthogonal reactions. At present, bioorthogonal reactions are shown in table 1, wherein any one of the reactive groups can be used as a bioorthogonal group for the functional modification of chitosan coating, including dibenzocyclooctyne used in SPAAC reaction, cyclooctene used in iedd reaction, cyclooctyne used in SPOQC reaction, ortho-substituted triphenylphosphine group used in Staudinger-bertozizi ligation reaction, and derivatives of Nitrone used in Nitrone-alkyne cyclic addition reaction.
TABLE 1
Figure BDA0003399597180000061
Example 1
This example provides a circulating tumor cell detection material that is a bioorthogonal/anti-adhesion bifunctional chitosan coating. Wherein "bioorthogonal" refers to groups having bioorthogonal reactivity, including eight-membered cyclooctyne and ortho-substituted triphenylphosphine groups used in Staudinger-Bertozzi ligation. "anti-adhesion" refers to a functionalized chitosan coating having both a hydrophilic chitosan structure and a hydrophobic bioorthogonal structure. The preparation method of the bioorthogonal/anti-adhesion bifunctional chitosan coating comprises the preparation of the chitosan coating and the functional modification of the chitosan coating, and comprises the following specific steps:
preparing a chitosan coating: dissolving chitosan with deacetylation degree of 95% in acetic acid solution of 90%; spin-coating the substrate with the hydrophilic surface at 4000 rpm to obtain a chitosan coating, or preparing the chitosan coating on the substrate with the hydrophilic surface by using a 7-gauge needle, and performing electrostatic spinning under the conditions of 30s and 16 kv; drying the chitosan coating for 72 hours at 60 ℃; and adjusting the pH value to expose the amino group of the chitosan. Among them, the substrate material having a hydrophilic surface may be selected from glass, silicon wafer, mica, and the like.
Functional modification of the chitosan coating: the structure of the functionalized chitosan is shown as formulas IA, IB, IC and ID, and the general synthesis mode is as follows: reacting the chitosan coating with NHS activated ester containing A, B, C or D group in ethanol containing 5% triethylamine for 24 hours; 5 times of ethanol washing with 5% triethylamine, 3 times of water washing with 5% triethylamine, and 3 times of water washing; drying for 1 hour at 60 ℃.
Figure BDA0003399597180000071
Wherein R has a structure represented by formula A, B, C or D,
Figure BDA0003399597180000072
in a specific embodiment, the functionalized chitosan has the structure shown in formula IA, the bio-orthogonal/anti-adhesion bifunctional group is Dibenzocyclooctyne (DBCO), and the reaction formula of the bio-orthogonal/anti-adhesion bifunctional chitosan coating is as follows:
Figure BDA0003399597180000073
in a specific embodiment, the present invention provides a detector for circulating tumor cells, comprising a substrate and the above-mentioned detection material for circulating tumor cells fixed on the substrate. The substrate is selected from a microfluidic chip substrate, a magnetic nanoparticle material substrate and other material substrates capable of being subjected to hydrophilic treatment.
Example 2
The embodiment provides a detection material for circulating tumor cells, which is a bioorthogonal/anti-adhesion/reversible release tri-functional chitosan coating. Wherein "bioorthogonal" refers to groups having bioorthogonal reactivity, including eight-membered cyclooctyne and ortho-substituted triphenylphosphine groups used in Staudinger-Bertozzi ligation. "anti-adhesion" refers to a functionalized chitosan coating having both a hydrophilic chitosan structure and a hydrophobic bioorthogonal structure. "reversibly released" refers to having a reversible cleavage group, thereby releasing the captured circulating tumor cells. The preparation method of the bioorthogonal/anti-adhesion/reversible release three-functional chitosan coating comprises the preparation of the chitosan coating and the functional modification of the chitosan coating, and comprises the following specific steps:
preparing a chitosan coating: dissolving chitosan with deacetylation degree of 95% in acetic acid solution of 90%; spin-coating the substrate with the hydrophilic surface at 2.4000 rpm to obtain a chitosan coating, or preparing the chitosan coating on the substrate with the hydrophilic surface by using a 7-gauge needle, and carrying out electrostatic spinning under the conditions of 30s and 16 kv; drying the chitosan coating for 72 hours at 60 ℃; and adjusting the pH value to expose the amino group of the chitosan. Among them, the substrate material having a hydrophilic surface may be selected from glass, silicon wafer, mica, and the like.
Functional modification of the chitosan coating: the structure of the functionalized chitosan is shown in formulas IIA, IIB, IIC and IID, and the general synthesis mode is as follows: reacting the chitosan coating with coupling molecules SPDP in ethanol containing 5% of triethylamine for 24 hours; 5 times of ethanol washing with 5% triethylamine, 3 times of water washing with 5% triethylamine, and 3 times of water washing; drying for 1 hour at 60 ℃; reacting with a sulfhydryl-modified molecule containing A, B, C or D groups in ethanol for 24 hours; washing with ethanol for 5 times, and washing with water for 5 times; drying for 1 hour at 60 ℃.
Figure BDA0003399597180000081
Wherein R has a structure represented by formula A, B, C or D,
Figure BDA0003399597180000082
in a specific embodiment, the functionalized chitosan has the structure shown in formula IIA, the reversible cleavage group is a disulfide bond, the bio-orthogonal/anti-adhesion bifunctional group is Dibenzocyclooctyne (DBCO), and the bio-orthogonal/anti-adhesion/reversible release trifunctional chitosan coating has the following reaction formula:
Figure BDA0003399597180000091
in a specific embodiment, the present invention provides a detector for circulating tumor cells, comprising a substrate and the above-mentioned detection material for circulating tumor cells fixed on the substrate. The substrate is selected from a microfluidic chip substrate, a magnetic nanoparticle material substrate and other material substrates capable of being subjected to hydrophilic treatment.
Example 3
This example provides the whole detection process of hepatoma CTC based on bioorthogonal/anti-adhesion bifunctional chitosan coating, which is performed step by step in the manner of "pretreatment of clinical blood sample-artificial labeling of metabolic sugar engineering-co-incubation of detector and sample" (FIG. 1A). The method comprises the following specific steps:
pretreatment of clinical blood samples: blood of 5ml of a patient is collected by an anticoagulation tube, CTC is primarily enriched by using a density gradient centrifugation mode, and residual erythrocytes are removed by using erythrocyte lysate.
Artificial marking of metabolic sugar engineering: ac with 100uM4ManAz is subjected to 48-hour metabolic sugar engineering treatment, and the treatment method refers to Chinese patent CN 113358865A.
Detector and sample co-incubation: the metabolic glycoengineering samples were incubated with approximately 200mm in 1ml of DMEM medium2Detector co-incubation (standing or slow flow-through) washes away other blood components that do not adhere to the detector, resulting in CTCs adhering to the detector surface.
The method comprises the following steps of (1) performing functionalized chitosan biological coating treatment by using a hydrophilized vitreous micro-fluidic chip as a substrate, wherein the structure of the functionalized chitosan is shown as formula IA, preparing a bioorthogonal/anti-adhesion bifunctional detector, and capturing CTC of a liver cancer patient according to the results shown in Table 2:
TABLE 2
Figure BDA0003399597180000092
Figure BDA0003399597180000101
Example 4
The whole detection process is gradually carried out in a mode of 'clinical blood sample pretreatment-metabolic sugar engineering artificial marking-detector and sample co-incubation-liver cancer CTC reversible release' (fig. 1B). The method comprises the following specific steps:
pretreatment of clinical blood samples: blood of 5ml of a patient is collected by an anticoagulation tube, CTC is primarily enriched by using a density gradient centrifugation mode, and residual erythrocytes are removed by using erythrocyte lysate.
Artificial marking of metabolic sugar engineering: ac with 100uM4ManAz was subjected to a 48 hour metabolic glycoengineering treatment. The treatment method of metabolic sugar engineering refers to Chinese patent CN 113358865A.
Detector and sample co-incubation: the metabolic glycoengineering samples were incubated with approximately 200mm in 1ml of DMEM medium2Detector co-incubation (standing or slow flow-through) washes away other blood components that do not adhere to the detector, resulting in CTCs adhering to the detector surface.
Reversible release of liver cancer CTCs: the detector was soaked with 10mM dithiothreitol in PBS for 30 minutes, and then the detector surface was rinsed with PBS to obtain released hepatoma CTCs.
In another specific embodiment, the reversibly reactive groups can be cleaved by modulating the electrical signal and/or temperature of the functionalized surface of the captured circulating tumor cell, or by selecting boronates as releasing molecules, as shown in FIG. 2.
The functional chitosan coating treatment is carried out by taking the glass micro-fluidic chip subjected to hydrophilic treatment as a substrate, the structure of the functional chitosan is shown as formula IIA, the bioorthogonal/anti-adhesion/reversible release three-function detector is prepared, and the results of capturing and releasing CTC of a liver cancer patient are shown in Table 3:
TABLE 3
Figure BDA0003399597180000102
Figure BDA0003399597180000111
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.

Claims (10)

1. The detection material for the circulating tumor cells is characterized in that the detection material is fixed on a substrate and is chitosan modified by functional groups;
(1) the functional group comprises a bio-orthogonal reactive group; or the like, or, alternatively,
(2) the functional groups include bio-orthogonal reactive groups and reversible reactive groups.
2. The detection material of claim 1, wherein (1) when the functionalized group comprises a bio-orthogonal reactive group, the detection material has a structure represented by formula I,
Figure FDA0003399597170000011
the R is a bio-orthogonal reactive group;
preferably, R has a structure represented by formula A, B, C or D,
Figure FDA0003399597170000012
(2) when the functional group comprises a bio-orthogonal reactive group and a reversible reactive group, the reversible reactive group is a disulfide bond;
preferably, the reversible reactive group serves as a linking arm to link the chitosan and the bio-orthogonal reactive group;
preferably, the detection material has a structure shown in the following formula II,
Figure FDA0003399597170000021
the R is a bio-orthogonal reactive group;
preferably, R has a structure represented by formula A, B, C or D,
Figure FDA0003399597170000022
3. the detection material according to claim 1 or 2, wherein the substrate has a hydrophilic surface;
preferably, the substrate is selected from hydrophilized glass, silicon wafers or mica.
4. A detector of circulating tumor cells, comprising a substrate and the detection material according to any one of claims 1 to 3 immobilized on the substrate.
5. The detector of claim 4, wherein the substrate has a hydrophilic surface;
preferably, the substrate is selected from a microfluidic chip substrate, a magnetic nanoparticle material substrate and other material substrates capable of being subjected to hydrophilization treatment.
6. A detection kit for circulating tumor cells, comprising a detection material according to any one of claims 1 to 3 or a detector according to claim 4 or 5 and a sugar unit-based labeling molecule;
preferably, the detection kit further comprises a release molecule;
preferably, the releasing molecule is dithiothreitol and/or a borate;
preferably, the sugar unit-based labeling molecule is selected from one or more of a 2-amino mannose unit, a 2-amino galactose unit, a 2-amino glucose unit and a 6-azide-L-fucose unit;
the 2-amino mannose unit, the 2-amino galactose unit, the 2-amino glucose unit and the 6-azido-L-fucose unit have the following structures,
Figure FDA0003399597170000031
wherein X is (CH)2)n
7. Use of the circulating tumor cell detection material according to any one of claims 1 to 3, the circulating tumor cell detector according to claim 4 or 5, or the circulating tumor cell detection kit according to claim 6 for circulating tumor cell detection;
preferably, the circulating tumor cell is a circulating tumor cell of liver cancer.
8. A method for preparing a circulating tumor cell detecting material according to any one of claims 1 to 3, comprising the steps of:
preparing a chitosan coating: preparing a chitosan coating on the surface of a substrate material, and adjusting the pH value to expose chitosan amino;
functional modification of the chitosan coating: connecting a bio-orthogonal reaction group or a bio-orthogonal reaction group and a reversible reaction group on a chitosan molecule;
preferably, uniformly spreading acetic acid solution of chitosan on the surface of the substrate material, drying and adjusting pH to obtain a chitosan coating;
preferably, the acetic acid solution of chitosan is uniformly spread on the surface of the substrate material by means of spin coating or electrostatic spinning;
preferably, the chitosan has a degree of deacetylation of 95%;
preferably, the volume percentage of the acetic acid solution is 90%.
9. The method according to claim 8, wherein when the functionalized group comprises a bio-orthogonal reactive group, the chitosan coating is functionally modified by reacting the chitosan coating with the NHS activated ester containing the bio-orthogonal reactive group in ethanol containing 5% triethylamine for 24 hours; 5 times of ethanol washing with 5% triethylamine, 3 times of water washing with 5% triethylamine, and 3 times of water washing; drying for 1 hour at 60 ℃;
when the functional groups comprise bio-orthogonal reaction groups and reversible reaction groups, the functional modification method of the chitosan coating is that the chitosan coating reacts with coupling molecules SPDP in ethanol containing 5% of triethylamine for 24 hours; 5 times of ethanol washing with 5% triethylamine, 3 times of water washing with 5% triethylamine, and 3 times of water washing; drying for 1 hour at 60 ℃; reacting with thiol-modified bio-orthogonal reactive group-containing molecules in ethanol for 24 hours; washing with ethanol for 5 times, and washing with water for 5 times; drying for 1 hour at 60 ℃.
10. A method for detecting circulating tumor cells, comprising the steps of:
processing a sample by using a marker molecule based on a sugar unit, and artificially marking the circulating tumor cells by the marker molecule through metabolic sugar engineering;
incubating circulating tumor cells with the detection material of any one of claims 1-3 or the detector of claim 4 or 5, wherein the bio-orthogonal reactive group is bio-orthogonally reactive with the labeling molecule, and the circulating tumor cells are captured;
preferably, when the functionalized groups include bio-orthogonal reactive groups and reversible reactive groups, the detection method further comprises releasing the captured circulating tumor cells, in particular: cleaving the reversible reactive group to release the captured circulating tumor cell by adding a release molecule to the captured circulating tumor cell or by modulating an electrical signal and/or temperature of the functionalized surface of the captured circulating tumor cell;
preferably, the releasing molecule is dithiothreitol and/or a borate;
preferably, the circulating tumor cell is a circulating tumor cell of liver cancer.
CN202111494317.1A 2021-12-08 2021-12-08 Detection material, detector and detection method for circulating tumor cells Active CN114478828B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202111494317.1A CN114478828B (en) 2021-12-08 2021-12-08 Detection material, detector and detection method for circulating tumor cells
PCT/CN2022/137032 WO2023104059A1 (en) 2021-12-08 2022-12-06 Circulating tumor cell detection material, detector and detection method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111494317.1A CN114478828B (en) 2021-12-08 2021-12-08 Detection material, detector and detection method for circulating tumor cells

Publications (2)

Publication Number Publication Date
CN114478828A true CN114478828A (en) 2022-05-13
CN114478828B CN114478828B (en) 2023-03-31

Family

ID=81492037

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111494317.1A Active CN114478828B (en) 2021-12-08 2021-12-08 Detection material, detector and detection method for circulating tumor cells

Country Status (2)

Country Link
CN (1) CN114478828B (en)
WO (1) WO2023104059A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023104059A1 (en) * 2021-12-08 2023-06-15 深圳先进技术研究院 Circulating tumor cell detection material, detector and detection method

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2503009A1 (en) * 2011-03-25 2012-09-26 Massimo Zollo Biomarker for detecting circulating tumor cells and related detecting methods and kit
US20130197296A1 (en) * 2012-01-13 2013-08-01 Karl-Heinz Ott Removing Cells from an Organism
US20150125879A1 (en) * 2013-09-25 2015-05-07 Massachusetts Institute Of Technology Biodegradable Layer-by-Layer (LbL) Films for Cell Capture and Release
CN104619856A (en) * 2012-05-29 2015-05-13 加利福尼亚大学董事会 Systems, methods and components for isolating cells from a fluid sample
CN106148315A (en) * 2015-04-14 2016-11-23 中国科学院苏州纳米技术与纳米仿生研究所 A kind of CTC based on chitin nanometer capture and purification substrate and preparation method thereof
CN106170304A (en) * 2015-03-23 2016-11-30 北京大学深圳研究生院 Bio-orthogonal reagent, activator and precursor and bio-orthogonal test kit
CN107641618A (en) * 2016-07-22 2018-01-30 中国科学院苏州纳米技术与纳米仿生研究所 The application of nanofiber substrate and preparation method thereof, nanofiber substrate
CN109187978A (en) * 2018-08-10 2019-01-11 北京莱尔生物医药科技有限公司 It is a kind of detect circulating tumor cell HER2, ER, PR immunofluorescent reagent box and its application
CN110101684A (en) * 2019-05-15 2019-08-09 深圳先进技术研究院 A kind of cellular membrane biomimetic nano particle and its preparation method and application of bio-orthogonal targeting
CN110133267A (en) * 2019-06-18 2019-08-16 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 It is a kind of for adsorbing the carrier of tumour cell, preparation method, kit and application
CN110514489A (en) * 2019-06-05 2019-11-29 南开大学 A kind of biological coating and preparation method thereof of the specific whole blood capture circulating tumor cell for cancer surveillance
CN111093708A (en) * 2017-04-07 2020-05-01 坦伯公司 Bioorthogonal compositions
CN112011513A (en) * 2020-09-04 2020-12-01 四川大学 Method for capturing high-purity circulating tumor cells based on bioorthogonal chemical method
CN112014563A (en) * 2020-08-27 2020-12-01 武汉大学 Molecular beacon transmission system for directly detecting circulating tumor cells in blood, preparation method and application thereof
CN113358865A (en) * 2020-03-03 2021-09-07 深圳先进技术研究院 Circulating tumor cell detection method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1243013C (en) * 2004-03-19 2006-02-22 华东师范大学 Adherence peptide specific to tissue of liver cancer, screen method combined between in vivo and in vitro, and usage
US11112410B2 (en) * 2016-04-13 2021-09-07 President And Fellows Of Harvard College Methods for capturing, isolation, and targeting of circulating tumor cells and diagnostic and therapeutic applications thereof
CN112370537B (en) * 2020-11-15 2023-08-11 大连理工大学 Double-targeting magnetic fluorescent nanoparticle, preparation method thereof and application thereof in liver cancer circulating tumor cells
CN114478828B (en) * 2021-12-08 2023-03-31 深圳先进技术研究院 Detection material, detector and detection method for circulating tumor cells

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2503009A1 (en) * 2011-03-25 2012-09-26 Massimo Zollo Biomarker for detecting circulating tumor cells and related detecting methods and kit
US20130197296A1 (en) * 2012-01-13 2013-08-01 Karl-Heinz Ott Removing Cells from an Organism
CN104619856A (en) * 2012-05-29 2015-05-13 加利福尼亚大学董事会 Systems, methods and components for isolating cells from a fluid sample
US20150125879A1 (en) * 2013-09-25 2015-05-07 Massachusetts Institute Of Technology Biodegradable Layer-by-Layer (LbL) Films for Cell Capture and Release
CN106170304A (en) * 2015-03-23 2016-11-30 北京大学深圳研究生院 Bio-orthogonal reagent, activator and precursor and bio-orthogonal test kit
CN106148315A (en) * 2015-04-14 2016-11-23 中国科学院苏州纳米技术与纳米仿生研究所 A kind of CTC based on chitin nanometer capture and purification substrate and preparation method thereof
CN107641618A (en) * 2016-07-22 2018-01-30 中国科学院苏州纳米技术与纳米仿生研究所 The application of nanofiber substrate and preparation method thereof, nanofiber substrate
CN111093708A (en) * 2017-04-07 2020-05-01 坦伯公司 Bioorthogonal compositions
CN109187978A (en) * 2018-08-10 2019-01-11 北京莱尔生物医药科技有限公司 It is a kind of detect circulating tumor cell HER2, ER, PR immunofluorescent reagent box and its application
CN110101684A (en) * 2019-05-15 2019-08-09 深圳先进技术研究院 A kind of cellular membrane biomimetic nano particle and its preparation method and application of bio-orthogonal targeting
CN110514489A (en) * 2019-06-05 2019-11-29 南开大学 A kind of biological coating and preparation method thereof of the specific whole blood capture circulating tumor cell for cancer surveillance
CN110133267A (en) * 2019-06-18 2019-08-16 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 It is a kind of for adsorbing the carrier of tumour cell, preparation method, kit and application
CN113358865A (en) * 2020-03-03 2021-09-07 深圳先进技术研究院 Circulating tumor cell detection method
CN112014563A (en) * 2020-08-27 2020-12-01 武汉大学 Molecular beacon transmission system for directly detecting circulating tumor cells in blood, preparation method and application thereof
CN112011513A (en) * 2020-09-04 2020-12-01 四川大学 Method for capturing high-purity circulating tumor cells based on bioorthogonal chemical method

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023104059A1 (en) * 2021-12-08 2023-06-15 深圳先进技术研究院 Circulating tumor cell detection material, detector and detection method

Also Published As

Publication number Publication date
WO2023104059A1 (en) 2023-06-15
CN114478828B (en) 2023-03-31

Similar Documents

Publication Publication Date Title
CN102892900B (en) Method for separating target cell
EP3159694A1 (en) Sandwich assay using labeled lectin and kit therefor
CN111638364B (en) GDF15 rapid quantitative fluorescent microsphere detection device and preparation method thereof
CN104568923A (en) Method and kit for detecting circulating tumor cell antigens in peripheral blood through electrochemical luminescence detection
CN114478828B (en) Detection material, detector and detection method for circulating tumor cells
CN110514489A (en) A kind of biological coating and preparation method thereof of the specific whole blood capture circulating tumor cell for cancer surveillance
CN112062755B (en) Near-infrared fluorescent molecular probe for detecting aspartyl aminopeptidase, preparation method and application
CN113607948A (en) Application of detecting content of Glypican-1 protein in serum in evaluating pancreatic cancer occurrence development and stage judgment
CN109270274A (en) It is a kind of can in quantitative detection peripheral blood c reactive protein content test strips and preparation method
EP3243076A1 (en) Methods for detecting a marker for active tuberculosis
CN106841128B (en) Application of high-specificity fluorescent probe for detecting human serum albumin
CN103048453B (en) Nanometer magnetic particle chemiluminescence detection kit for carbohydrate antigen CA19-9 as well as preparation method thereof and detecting method thereof
JP2004502149A (en) Polymer for binding phenol
CN109682875A (en) Nucleic acid Electrochemical Detection system and detection method for hepatocellular carcinoma screening
CN202583209U (en) Optical excitation chemiluminiscence detection kit of pepsinogen I
CN107621492A (en) Biology sensor preparation method for the detection of the sialylated glycans of α 2,3
JP7081861B1 (en) A kit for testing urothelial cancer that identifies Neu5Gc in urine modified with UMOD based on LIP, and a method for producing the same.
CN111638363B (en) 3-deoxyfructose rapid quantitative fluorescence detection device and preparation method thereof
EP3358352B1 (en) Method for estimating pathological tissue diagnosis result (gleason score) of prostate cancer
CN112098648B (en) Method for detecting serum biomarker of liver cancer patient
JP5219014B2 (en) Direct surface immobilization method of saccharide, method of detecting interaction between saccharide and protein
CN110420671A (en) A kind of agglutinin micro-array chip and preparation method thereof
CN114323863B (en) Preparation method and application of exosome array capture probe
CN109323996A (en) A kind of fungal detection kit
CN109946270A (en) A kind of application of the CdTe quantum probe of beta-cyclodextrin modified in detection pesticide chlopyrifos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant